EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Open Orphan plc (OPORF) fair value: what the stock is really worth

As of Sep 18, 2026: fair value of Open Orphan plc $0.12, price $0.11, upside +9.5%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

OO Open Orphan plc logo Thin data Sep 23, 2026

Open Orphan plc

OPORF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.1200 · Fairly valued (+9%)
!Quality 37/100
!Weak Growth (revenue 5y +17.8 %/yr)
!Loss-making · -12.1% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (4/11)
!Narrow moat 3/100
!Insider activity 45/100
!Evidence only low, so the estimate is less certain
Watch Open Orphan plc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.5154 $0.0861 Fair Value $0.1200 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.0861 – $0.5154 · fair‑value band $0.0900 – $0.1400 · the $0.1096 price screens below the $0.1200 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Open Orphan in your weekly email

Every Wednesday you see whether Open Orphan is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services.

Show more

hVIVO plc operates as a full-service early specialist contract research organisation in the United Kingdom, Europe, and North America. It provides end-to-end early clinical development services to the biopharmaceutical industry, including phase I capabilities and world leading human challenge trial services. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including virology, immunology and biomarker analysis, as well as assay development, sample analysis, and data interpretation. In addition, the company offers services combined with specialisms in infectious diseases, respiratory, and cardiometabolic therapeutical areas. Further, it provides pre­clinical and early clinical research services; sales and marketing services; data management; storage solutions; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

Stock analysis

Open Orphan plc (OPORF) currently trades at $0.1096, while our model-based Fair Value estimate is $0.1200, implying the stock looks roughly 8.7% fairly valued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $0.1100 per share, and 1 of the 4 models we run sit above the $0.1096 price.

Bear case: the Dividend Discount group reads lowest at $0.0200, and 3 of the 4 models stay below the price. Evidence for this calculation is low.

Scenario range: $0.0900 (bear) to $0.1400 (bull), the price of $0.1096 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Open Orphan plc reported revenue of £46.8M in FY2025 versus £36.9M in FY2021, a compound +6.1%/yr. Reported net income was −£6.0M in FY2025.

Key figures

Market cap $75.2M · P/S ratio 1.52 · EPS (TTM) $−0.0100 · Dividend yield 1.8% · Net margin −12.8% · Return on equity −14.5% · Return on assets (EBIT) 7.8% · Operating margin −17.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 54% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 9%, OPORF screens cheaper than that median.

Fair Value models

Bear $0.0900 Fair Value $0.1200 Bull $0.1400
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA $0.0900 $0.1100 $0.1300 67
Gordon GGM $0.0100 $0.0200 $0.0300 64
DDM Multi-Stage $0.0100 $0.0200 $0.0300 63
All 4 models by family
Dividend Discount
Gordon GGM $0.0100 $0.0200 $0.0300 64
DDM Multi-Stage $0.0100 $0.0200 $0.0300 63
Multiples
EV/EBITDA $0.0900 $0.1100 $0.1300 67
Asset-Based
NCAV (Graham) $0.0300 $0.0400 $0.0600 54

Open the full fair value analysis →

Notify me when OPORF reaches fair value

Put OPORF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 42 · Market factors (momentum, volatility) 26

Profitability 9
Margins and returns on capital today
Quality Growth 5
Are margins and returns improving?
Cashflow 33
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 45
Disciplined investing over empire-building
Low Volatility 3
Calm price path (market factor)
Momentum 52
Price trend over the last 3–12 months (market factor)
52W Momentum 8
Distance to the 52-week high (market factor)
Net Issuance 80
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 30/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−25.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.8%
Start year 2020 (pandemic). Over 10 years: +18.6% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−49.8% (2020) → −0.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch OPORF, get fair value alerts →

Compare Open Orphan plc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 143 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside +10% · Top 25%
Profitability
Return on assets −3% · Below median
Net margin (TTM) −12% · Bottom 25%
Operating margin (TTM) −18% · Bottom 25%
Growth and dividend
Revenue growth −17% · Bottom 25%
Dividend yield (TTM) 1.8% · Above median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/B 1.97× · Pricier than median
P/S (TTM) 1.51× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)46 · sector 0
FUTURE (revenue growth)0 · sector 28
PAST (return on equity)0 · sector 8
HEALTH (low debt)99 · sector 95
DIVIDEND (yield)36 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $678.39 $686.04 +1%
Danaher Corporation DHR $223.77 $209.18 −7%
WuXi AppTec Co 2359 HK$207.60 HK$228.36 +10%
Lonza Group LONN CHF 570.00 CHF 151.69 −73%
IDEXX Laboratories, Inc IDXX $522.02 $495.84 −5%
Agilent Technologies, Inc A $165.32 $63.90 −61%
Waters Corporation WAT $425.74 $106.31 −75%
IQVIA Holdings IQV $270.09 $295.80 +10%
Illumina, Inc ILMN $255.38 $280.92 +10%
Mettler-Toledo International Inc MTD $1,491 $635.75 −57%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Open Orphan plc · Fair Value
$0.1200 +9%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Open Orphan plc Fair Value". https://www.fairvalue-calculator.com/stock/OPORF

Frequently asked questions

Is Open Orphan plc (OPORF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.1200 versus the last price from Sep 18, 2026 of $0.1096, about +9% upside (fairly valued).
What is the fair value of OPORF?
Our model-based fair value for Open Orphan plc is $0.1200 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.1096.
What is the quality score of OPORF?
Open Orphan plc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Open Orphan plc (OPORF)?
Our model-based price target is the fair value of $0.1200 (as of Sep 23, 2026) from 4 valuation models. Cautious scenario $0.0900, optimistic scenario $0.1400. It is a calculation from audited fundamentals, not an analyst target.
What is the Open Orphan plc stock forecast for 2026?
Our models put fair value at $0.1200, about +9% upside versus the last price from Sep 18, 2026 of $0.1096 (fairly valued). Cautious scenario $0.0900, optimistic scenario $0.1400. The calculation is refreshed regularly with new filings.
What is the revenue of Open Orphan plc (OPORF)?
Open Orphan plc reported trailing-twelve-month revenue of about £49.7M (latest available figure, as of Sep 23, 2026).
Does Open Orphan plc pay a dividend?
Open Orphan plc currently shows a dividend yield of about 1.82% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Open Orphan plc (OPORF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Open Orphan plc it is $0.1200 per share (as of Sep 23, 2026), against a price of $0.1096. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Open Orphan plc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, OPORF trades below its calculated fair value: price $0.1096, fair value $0.1200, a gap of about +9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPORF?
No. The price is what the market pays today ($0.1096); the fair value is what the company's own numbers justify ($0.1200). For Open Orphan plc the two are $0.0104 per share apart. That gap is exactly why we show both numbers side by side.
How much is Open Orphan plc worth?
The market values Open Orphan plc at about $75.2M (market capitalisation, as of Sep 23, 2026). Per share that is $0.1096; our models calculate a fair value of $0.1200 per share.
What do the bullish and bearish scenarios say about OPORF?
Our models span a range for Open Orphan plc: cautious scenario $0.0900, base $0.1200, optimistic $0.1400 per share (as of Sep 23, 2026, price $0.1096). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Open Orphan plc (OPORF)?
Balance-sheet figures for Open Orphan plc (as of Sep 23, 2026): return on equity −14.5%, debt of 0.03 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is OPORF from its 52-week high?
Open Orphan plc trades at $0.1096, about 54% below its 52-week high of $0.2400 and 27% above the low of $0.0861 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1200 is for.
Which stocks are comparable to Open Orphan plc?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Lonza Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Open Orphan plc stock attractive at the current price?
The data as of Sep 23, 2026: price $0.1096, calculated fair value $0.1200 (+9%), Quality Score 37/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of OPORF calculated?
We run Open Orphan plc through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.1200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Open Orphan plc currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Open Orphan plc (OPORF)?
The latest price we hold is from Sep 18, 2026 and stands at $0.1096. Our model-based fair value is $0.1200, about +9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Open Orphan plc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Open Orphan plc

How large is the market capitalisation of Open Orphan plc (OPORF)?
The market capitalisation of Open Orphan plc is $75.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Open Orphan plc (OPORF)?
The price-to-sales ratio of Open Orphan plc is 1.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Open Orphan plc (OPORF)?
Earnings per share at Open Orphan plc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Open Orphan plc (OPORF)?
The dividend yield of Open Orphan plc is 1.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Open Orphan plc (OPORF)?
The net margin of Open Orphan plc is −12.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Open Orphan plc (OPORF)?
The return on equity (ROE) of Open Orphan plc is −14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Open Orphan plc (OPORF)?
On an EBIT basis the return on assets of Open Orphan plc is 7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Open Orphan plc (OPORF)?
The operating margin of Open Orphan plc is −17.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Open Orphan plc (OPORF)?
Revenue at Open Orphan plc is growing −16.6% versus a year earlier (3y avg −2.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Open Orphan plc (OPORF)?
Earnings per share at Open Orphan plc are growing −55.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Open Orphan plc (OPORF) generate?
The free cash flow of Open Orphan plc is −£14.8M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Open Orphan plc (OPORF) carry?
The net debt of Open Orphan plc is £490K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Open Orphan plc in the live analysis

One click puts Open Orphan plc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.